ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 8,700 shares, a decline of 5.4% from the August 15th total of 9,200 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is presently 0.6 days.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A number of large investors have recently made changes to their positions in BIB. IMC Chicago LLC bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter valued at $2,435,000. Clarity Capital Partners LLC bought a new position in ProShares Ultra Nasdaq Biotechnology in the 4th quarter worth about $201,000. Toth Financial Advisory Corp grew its holdings in ProShares Ultra Nasdaq Biotechnology by 132.3% during the 1st quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after buying an additional 14,870 shares in the last quarter. Westwood Wealth Management bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the first quarter valued at about $575,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the first quarter worth about $288,000.
ProShares Ultra Nasdaq Biotechnology Stock Performance
Shares of BIB stock opened at $66.68 on Thursday. The firm’s 50 day moving average is $65.29 and its 200 day moving average is $59.29. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $40.10 and a 12 month high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Intuitive Machines Soars: NASA Contract Fuels Lunar Ambitions
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Beaten-Down Stocks Ready for a Comeback
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks to Neutralize Market Volatility and Build Wealth
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.